Navigation Links
MIGENIX releases CEO message #22
Date:2/15/2008

tential regulatory filings, including acceptance and approval of an NDA, for OmigardTM; Cutanea Life Sciences' ability to manage, fund and advance CLS001 into Phase III; the adequacy of the CLS001 Phase II results for regulatory authorities to support advancing to Phase III; our ability to manage licensing opportunities and arrangements; our ability to initiate, fund and complete non-clinical studies, clinical studies, manufacturing and all ancillary activities within our expected timelines; and future expense levels being within our current expectations.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and other factors including: dependence on corporate collaborations; potential delays; uncertainties related to early stage of technology and product development; uncertainties as to the requirement that a drug be found to be safe and effective after extensive clinical trials and the possibility that the results of such trials, if completed, will not establish the safety or efficacy of our products; uncertainties as to future expense levels and the possibility of unanticipated costs or expenses or cost overruns; the possibility that opportunities will arise that require more cash than presently anticipated and other uncertainties related to predictions of future cash requirements; and other risks and uncertainties which may not be described herein. Certain of these factors and other factors are described in detail in the Company's Annual Information Form and Annual Report on Form 20-F for and other filings with the Canadian securities regulatory authorities and the U.S. Securities & Exchange Commission.

Forward-looking statements are based on our current expectations and MIGENIX assumes no obligations to update such information to reflect later events or development
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
2. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
3. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
6. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
7. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
8. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
9. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
10. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
11. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics including high value ... closing of its previously announced underwritten public offering ... a public offering price of $15.50 per share. ... underwriters of their option to purchase up to ...
(Date:4/30/2015)... FRANCE (PRWEB) April 30, 2015 ... and at http://www.lespausa.com , Fleur’s ... multi-action product combining the benefits of makeup, skin ... This subtly tinted cream is designed with specific ... for an even complexion and a healthy glow. ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Sterlitech ... ultrafiltration membranes, the PX, PY, and PZ ... sheets, and disks. Designed to be ideal ... new membranes can fill critical process requirements where ... downstream processes. , “New regulations on industrial wastewater ...
(Date:4/29/2015)... --  Doximity , the leading online medical network with ... announced a new, instant method for physicians to apply ... click, all US physicians can quickly submit their verified ... open job opportunity, and a recruiter will reach out ... of physicians are open to new jobs, and yet ...
Breaking Biology Technology:Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Sterlitech Offers New Ultrafiltration Membranes 2Doximity Offering Hospitals Easy, Efficient Physician Application Tool 2
... April 29 A new, free white ... available from Spiral,Biotech, Inc. at: http://www.aicompanies.com/anoxomat ... isolating and identifying anaerobic bacteria in organisms., ... patient health, modern,clinical laboratories must ensure accurate, ...
... April 29 Core Informatics announces,that it has ... product,to BioRelix Pharmaceuticals of New Haven, CT. BioRelix, ... need to establish a,strong data management infrastructure from ... LIMS marketplace, BioRelix choose the Core LIMS., ...
... Aflac and the American,Association for Cancer Research ... Career Development Award for Childhood Cancer Research,endowed by ... pediatric cancer. The award,which includes a two-year grant ... Meeting in San Diego, Calif., to Dr. Charles ...
Cached Biology Technology:White Paper Details New Techniques for Isolating, Identifying Anaerobic Bacteria and Organisms 2Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals 2Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research 2Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research 3
(Date:4/2/2015)... 2015 Fingerprint Cards (FPC) has ... from the distributor World Peace Industrial Group (WPI), part ... although the major part of the shipments will take ... by smartphone manufacturers in China . ... the communicated revenue guidance of + 1 000 MSEK for ...
(Date:3/30/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ... Gesture Recognition Market in Automotive Sector 2014-2018" report ... Global Gesture Recognition market in Automotive Sector to grow ... Gesture recognition is the ability of a ... an individual. Gesture recognition technology can be 2D-based or ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... the University of Turin, Italy and the University of ... may help the medical community to determine the genetic ... in an article published March 21st in the open-access ... diseases originate from mutations in one or more genes. ...
... after most of Costa Rica,s rainforests were cut down, researchers ... many thought was impossible - restoring a tropical rainforest ecosystem. ... Rica with a sampling of local trees, native species began ... rainforests can one day be replaced. Carl Leopold and ...
... in a patient lying on an operating table, while another ... be in a real OR or treatment room, except that ... made theyre robots., These high-tech, electronically outfitted mannequins are ... training center at the Johns Hopkins Outpatient Center in East ...
Cached Biology News:Can you rescue a rainforest? The answer may be yes 2Actor-robots 'staff' part of new $5M simulation training center 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: